Adenosine
CLINICAL USE
DOSE IN NORMAL RENAL FUNCTION
Initially: 3 mg over 2 seconds with cardiac
monitoring followed, if necessary, by 6 mg
after 1–2 minutes and then by 12 mg after a
further 1–2 minutes
PHARMACOKINETICS
267.2
0
<5
No data
Unchanged
DOSE IN RENAL IMPAIRMENT
GFR (mL/MIN)
Dose as in normal renal function
DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES
Not dialysed. Dose as in normal renal function
Not dialysed. Dose as in normal renal function
Unknown dialysability. Dose as in
normal renal function
Not dialysed. Dose as in normal renal function
IMPORTANT DRUG INTERACTIONS
Potentially hazardous interactions with other drugs
antipsychotics that prolong the QT
interval
is essential, dosage should be reduced by a
factor of 4 (i.e. initial dosage of 0.5–1 mg)
ADMINISTRATION
Reconstition
–
Route
IV
Rate of Administration
Rapid IV bolus (see dose)
Comments
Do not refrigerate
Administer into central vein, large
peripheral vein, or into an IV line. If IV
line used, follow dose by rapid sodium
chloride 0.9% flush
OTHER INFORMATION
adenosine, so dose adjustments are not
required in hepatic or renal insufficiency
and lightheadedness; the side effects are
short-lived